Asset
Aficamten
Cytokinetics Incorporated Common Stock
Revenue
No revenue reported in loaded filings.
Clinical trials (7)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT06412666 | phase2_3 | active_not_recruiting | 2024-05-29 | 2030-01-01 | Cytokinetics | A Study to Evaluate the Effect of Aficamten in Pediatric Patients With Symptomatic Obstructive Hypertrophic Cardiomyopathy (oHCM). |
| NCT06081894 | phase3 | active_not_recruiting | 2023-08-31 | 2026-08-01 | Cytokinetics | A Trial to Evaluate the Efficacy and Safety of Aficamten Compared to Placebo in Adults With Symptomatic Non-Obstructive Hypertrophic Cardiomyopathy (nHCM) |
| NCT04219826 | phase2 | completed | 2020-01-10 | 2023-02-28 | Cytokinetics | Dose-finding Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of CK-3773274 in Adults With Hypertrophic Cardiomyopathy |
| NCT04848506 | phase2_3 | enrolling_by_invitation | 2021-05-06 | 2028-03-01 | Cytokinetics | Open-label Extension Study to Evaluate the Long-term Safety and Tolerability of Aficamten in Adults With HCM |
| NCT05767346 | phase3 | completed | 2023-06-20 | 2025-02-28 | Cytokinetics | Phase 3 Trial to Evaluate the Efficacy and Safety of Aficamten Compared to Metoprolol Succinate in Adults With Symptomatic oHCM |
FDA applications (1)
| Application | Type | Applicant |
|---|---|---|
| NDA 219083 | NDA | CYTOKINETICS INC |
Marketed products (4)
- MYQORZO
- MYQORZO
- MYQORZO
- MYQORZO